Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer

NCT04164745 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

49

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Anlotinib, oral capsule
BIOLOGICAL: Pembrolizumab

Sponsor

Peking Union Medical College Hospital